China’s First CAR-T Is From Fosun Kite; Overseas Data Played Key Role

Fosun Kite Biotechnology Co Ltd's CD-19-targeting chimeric antigen receptor T-cell (CAR-T) therapy, FKC876, marketed globally as Yescarta (axicabtagene ciloleucel), has been approved in China as a third-line treatment for adult patients with diffuse B-cell lymphoma or relapsed and recurrent B-cell lymphoma.

The country’s first approval of a cell therapy is expected to open the door for more CAR-Ts at a time when the area is fast gaining traction